Study uncovers role for STING in regulating tumor response to DNA-damaging treatments
In a study by Yale Cancer Center, researchers report on the discovery of a new role for STimulator of INterferon Genes or STING. STING has traditionally been implicated in the immune response to DNA damage, however, in this study, the focus is on STING s role in the tumor DNA damage response. The findings may lead to improved treatments, including new combinations of therapies for patients diagnosed with head and neck cancers. The paper is published online today in the journal
Nature Communications. These results highlight a previously unknown role for STING in regulating the tumor response to DNA-damaging treatments, said Thomas Hayman, MD, PhD, Assistant Professor of Therapeutic Radiology at Yale Cancer Center and lead author of the study. Excitingly, our results support the clinical evaluation of STING agonists in combination with DNA-damaging treatments in patients with head and neck canc
F-star Therapeutics, Inc.: Study Published in Nature Shows F-Star s STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy
SB 11285 is a Second Generation STING Agonist Delivered Intravenously
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 19, 2021. The study entitled STING enhances cell death through regulation of reactive oxygen species and DNA damage demonstrates that systemic administration of a STING agonist in combination with radiation in a preclinical model enhances local control in Head and Neck Squamous Cell Carcinoma (HNSCC) and suggests that STING expression in the tumor is required for maximal therapeutic benefit. The studies described in this paper demonstrate that systemic administration of SB 11285, a novel STING agonist, in combination with radiation, enhances the antitumor effects in animal models of HNSCC. Furthermore, STING expression in the tumor can be used as a predictive biomarker and a combination of radiation with SB 11285 dem
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Study Published in Nature Shows F-Star’s STING Agonist SB 11285 Enhances Preclinical Efficacy .
F-star Therapeutics, Inc.April 19, 2021 GMT
SB 11285 in Combination with Radiation is More Effective than Either as Monotherapy in a Murine Tumor Model
SB 11285 is a Second Generation STING Agonist Delivered Intravenously
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced the publication of a new study, conducted by Yale University and F-star, of its second generation STING agonist, SB 11285, in the current issue of
Turn It Yellow Day GLASWEGIANS are being asked to support the Beatson Cancer Charity by wearing yellow to work at the end of the month. Turn It Yellow Day will take place on Thursday April, 29 and will ask employees to wear yellow as well as turning their workplace yellow as part of the fundraiser. It comes as part of the Beatson Cancer Charity s campaign to raise money for a new MRI scanner. Ethne McPherson, Head of Therapeutic Radiography at The Beatson West of Scotland Cancer Centre, said: “This MRI scanner allows us to visualise and outline tumours at a whole new level. Words cannot describe how valuable this is to future Radiotherapy planning and treatment.
Novel immunotherapy approach may offer therapeutic advantages for melanoma
In a new study led by Yale Cancer Center, researchers have advanced a tumor-targeting and cell penetrating antibody that can deliver payloads to stimulate an immune response to help treat melanoma. The study was presented today at the American Association of Cancer Research (AACR) virtual annual meeting.
Most approaches rely on direct injection into tumors of ribonucleic acids (RNAs) or other molecules to boost the immune response, but this is not practical in the clinic, especially for patients with advanced cancer. In this study, we can deliver immune stimulatory RNA to tumors in vivo following systemic administration.